Alimera Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALIM research report →
About the company
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness.
- CEO
- Richard S. Eiswirth Jr.
- IPO
- 2019
- Employees
- 154
- HQ
- Alpharetta, GA, US
Price Chart
- Market Cap
- $301.29M
- P/E
- -7.03
- P/S
- 3.73
- P/B
- 3.07
- EV/EBITDA
- -319.82
- Div Yield
- 0.00%
- Gross Margin
- 75.75%
- Op Margin
- -2.39%
- Net Margin
- -24.93%
- ROE
- -159.01%
- ROIC
- -1.46%
- Revenue
- $80.75M · 49.19%
- Net Income
- $-20,132,000 · -11.18%
- EPS
- $-0.79 · 69.50%
- Op Income
- $-1,932,000
- FCF YoY
- -777.74%
- 52W High
- $5.65
- 52W Low
- $2.61
- 50D MA
- $5.56
- 200D MA
- $4.17
- Beta
- 1.25
- Avg Volume
- 866.83K
Get TickerSpark's AI analysis on ALIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 24 | Maltz Elliot | sell | 75,000 |
| Sep 16, 24 | Maltz Elliot | sell | 75,000 |
| Sep 16, 24 | Maltz Elliot | sell | 75,000 |
| Sep 16, 24 | Kaseta Michael | sell | 1,825 |
| Sep 16, 24 | Kaseta Michael | sell | 50,000 |
| Sep 16, 24 | Snisarenko John | sell | 3,333 |
| Sep 16, 24 | Snisarenko John | sell | 46,150 |
| Sep 16, 24 | Snisarenko John | sell | 50,000 |
| Sep 16, 24 | Snisarenko John | sell | 6,000 |
| Sep 16, 24 | Snisarenko John | sell | 6,000 |
Our ALIM coverage
Recent articles, reports, and earnings notes.
No research on ALIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALIM report →Similar companies
Peers in the same neighborhood.